Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CSE/DRUG stock hub

CSE/DRUG has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CSE/DRUGis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.1B

Canadian Securities Exchange

Market data

Live price

Current market quote for this ticker.

Current price

CSE/DRUG

In the news

Latest news · CSE/DRUG

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 11P50 15.6P75 25.4

Trailing P/En/a

P25 7.4P50 15.6P75 34.3

ROE-27

P25 -121.5P50 -40.9P75 0.5

ROIC-15.9

P25 -72.5P50 -16P75 1.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CSE/DRUG market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

146

Groups with data

Currency

CAD

Showing 146 of 146 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	CA
Employees	26
Employees Change	25%
Employees Change Percent	2,500
Enterprise value	CAD 1B
Exchange	Canadian Securities Exchange
Financial currency	CAD
First seen	2026-05-10
Industry	Biotechnology
Isin	CA10919W4056
Last refreshed	2026-05-10
Market cap	CAD 1.1B
Price	CAD 113
Price currency	CAD
Sector	Healthcare
Sic	2836
Symbol	cse/DRUG
Website	https://brightmindsbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.8%
EV Earnings	-51x
P/B ratio	12.33x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	CAD -19.8M
Net Income Growth Years	0%
Profit Per Employee	CAD -763,241
ROA	-15.72
Roa5y	-40.07
ROCE	-21.02
ROE	-26.98
Roe5y	-69.2
ROIC	-15.92

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	168.68%
Cagr3y	205.31%
Cagr5y	31.89%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	CAD 90.9M
Cash	CAD 89M
Current Assets	CAD 90.8M
Current Liabilities	CAD 1.6M
Debt	CAD 104,900
Debt Equity	CAD 0
Equity	CAD 89.3M
Interest Coverage	-442.4
Liabilities	CAD 1.6M
Long Term Assets	CAD 92,179
Long Term Liabilities	CAD 16,744
Net Cash	CAD 88.9M
Net Cash By Market Cap	CAD 8.08
Net Cash Growth	54.11%
Net Debt Equity	CAD -1
Tangible Book Value	CAD 89.3M
Tangible Book Value Per Share	CAD 11.47
WACC	3.2

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	57.37
Net Working Capital	CAD 245,403
Quick ratio	56.59
Working Capital	CAD 89.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-48.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	168.5%
200-day SMA	88.46
3Y total return	2,748.1%
50-day SMA	111
50-day SMA vs 200-day SMA	50over200
5Y total return	298.94%
All Time High	170
All Time High Change	-33.82%
All Time High Date	2026-01-06
All Time Low	1.29
All Time Low Change	8,620.93%
All Time Low Date	2024-04-30
ATR	4.77
Beta	-0.19
Beta1y	1.99
Beta2y	22.59
Ch YTD	1.87
High	120.3
High52	170
High52 Date	2026-01-06
High52ch	-33.82%
Low	112.5
Low52	33.01
Low52 Date	2025-06-30
Low52ch	240.81%
Ma50ch	1.39%
Price vs 200-day SMA	27.18%
RSI	45.82
RSI Monthly	70.13
RSI Weekly	57.01
Sharpe ratio	1.01x
Sortino ratio	1.77
Total Return	-48.78%
Tr YTD	1.87
Tr1m	5.46%
Tr1w	-5.31%
Tr3m	7.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CAD -18.8M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6,732,185%
Net Borrowing	-102,385
Shares Insiders	16.38%
Shares Institutions	52.57%
Shares Out	9,787,161
Shares Qo Q	7.3%
Shares Yo Y	48.78%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,084.15x
Bv Per Share	11.47
Ch1m	5.46
Ch1w	-5.31
Ch1y	168.5
Ch3m	7.85
Ch3y	2,748.1
Ch5y	298.9
Ch6m	54.51
Change	-6.94%
Change From Open	-6.48
Close	120.9
Days Gap	-0.49
Depreciation Amortization	75,124
Dollar Volume	157,725
Earnings Date	2026-05-15
EBIT	CAD -18.8M
EPS	CAD -2.73
F Score	1
Financing CF	46,917,427
Fiscal Year End	September
Founded	2,017
Is Primary Listing	1
Last Earnings Date	2026-02-10
Last Report Date	2025-12-31
Last Split Date	2023-07-14
Last Split Type	Reverse
Ma150	103
Ma150ch	9.19%
Ma20	119.7
Ma20ch	-6.01%
Net CF	31,151,202
Next Earnings Date	2026-05-15
Open	120.3
Position In Range	0
Ppne	92,179
Price Date	2026-05-08
Ptbv Ratio	12.33
Relative Volume	1.33x
Share Based Comp	4,291,503
Tr6m	54.51%
Volume	1,402

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CSE/DRUG pay a dividend?

Capital-return profile for this ticker.

Performance

CSE/DRUG stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CSE/DRUG?

Insider, institutional, and short-interest positioning.

Institutional ownership

+52.6%

Share of float held by funds and institutions

Insider ownership

+16.4%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+48.8%

Negative means the company is buying back shares.

Technical

CSE/DRUG momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.8

Neutral momentum band

Price vs 200-day MA

+27.2%

50/200-day relationship not available

Beta (5Y)

-0.19

Less volatile than the market

Sharpe ratio

1.01

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CSE/DRUG

Hub-level FAQ points readers to the deeper analysis pages.

What is the current cse/DRUG stock rating?

cse/DRUG is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full cse/DRUG analysis?

The full report lives at /stocks/cse/DRUG/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for cse/DRUG?

The latest report frames cse/DRUG around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the cse/DRUG page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.